Bli medlem
Bli medlem

Du är här

2015-12-14

WntResearch: WntResearch has submitted phase 1b study application

WntResearch today announces that an application regarding permission
to start the Foxy-5 clinical phase 1b study has been submitted to the
Danish Health Authorities.

Nils Brünner, CEO: "This is a very important milestone for
WntResearch. I feel confident that the phase 1b study will provide us
with the information needed to optimize conditions for the pivotal
clinical phase 2 study. The major difference between the phase 1 and
1b studies and the phase 2 study lies in the recruitment of patients.
The phase 1 and 1b studies recruit patients who already have
metastatic disease and for whom the treating oncologist has no more
routine systemic treatment to offer. On the contrary, the phase 2
study will recruit only newly operated cancer patients with no signs
of persistent metastatic lesions. Thus, the phase 2 study will give
us the final answer to the anti-metastatic efficacy of Foxy-5."

For additional information please contact:
Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: + 45 2614 4708

About WntResearch
WntResearch AB is a public company on the AktieTorget in Sweden.
WntResearch develops the anti-cancer compound Foxy-5 to be used to
combat the metastatic process of cancer. WntResearch has one drug
candidate in clinical phase 1 - Foxy-5 - as well as one candidate
drug in preclinical development - Box-5. The Company is currently
focusing mainly on the development of Foxy-5.

-----------------------------------------------------------
http://news.cision.com/wntresearch/r/wntresearch-has-submitted-phase-1b-...
http://mb.cision.com/Main/11610/9884135/456579.pdf

Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.